Terns Pharmaceuticals Announces Conference Participation
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company, is making waves in the healthcare sector. Known for its innovative portfolio aimed at tackling serious diseases like oncology and obesity, Terns is gearing up for an important event that is sure to capture the interest of investors and the healthcare community alike.
Event Details and Significance
Members of Terns’ senior management team will take part in a presentation scheduled for a prominent healthcare conference. This event will take place on a Wednesday afternoon in the near future and is expected to start at 4:00 p.m. ET. Such presence at significant industry forums underscores Terns’ commitment to transparency and engagement with investors and stakeholders.
Live Webcast Accessibility
For those interested in following this event, Terns Pharmaceuticals will provide a live webcast. Investors and interested parties can tune in via the investor relations section of Terns’ website. Additionally, to ensure long-lasting accessibility of their insights, a replay of the presentation will remain available on Terns’ website for at least 30 days after the event concludes. This initiative reflects Terns' dedication to keeping its shareholders informed about their operations and advancements.
About Terns Pharmaceuticals’ Innovative Solutions
Terns Pharmaceuticals is at the forefront of drug development, targeting critical areas of healthcare. The company's research focuses primarily on small-molecule product candidates, offering promising solutions for complex diseases. Terns’ pipeline features several notable programs, including an allosteric BCR-ABL inhibitor and a small-molecule GLP-1 receptor agonist that showcases their innovative approach to treatment.
Research and Development Focus Areas
Among Terns’ key initiatives is the pursuit of a THR-? agonist and ongoing endeavors in preclinical exploration for a GIPR modulator, indicating the company’s diverse strategy in combating serious health issues. Their focus on a GIPR antagonist as a nomination candidate further highlights their proactive approach in discovering therapeutic candidates that could benefit a wide patient demographic.
Engaging with Stakeholders
Open communication with investors and the media forms the backbone of Terns Pharmaceuticals' strategy. The company has established dedicated points of contact for both groups, making it clear that they value interactions with their community. Justin Ng handles investor relations, while the media can reach out to Jenna Urban at Berry & Company Public Relations.
Contacting Terns Pharmaceuticals
Investors seeking additional details regarding the company’s performance or upcoming events can contact Justin Ng directly via the provided email for inquiries. Moreover, media professionals requiring press materials or interviews can connect with Jenna Urban, emphasizing Terns’ recognition of the importance of robust communication with all stakeholders.
Frequently Asked Questions
What is Terns Pharmaceuticals' focus area?
Terns Pharmaceuticals specializes in developing treatment solutions for critical diseases such as oncology and obesity through small-molecule product candidates.
When will Terns Pharmaceuticals participate in the conference?
Terns will present at the upcoming healthcare conference on a Wednesday afternoon at 4:00 p.m. ET.
How can I view the presentation?
The presentation will be streamed live on the investor relations page of Terns Pharmaceuticals’ website.
What does Terns’ product pipeline include?
The pipeline includes an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and other innovative therapies targeting various diseases.
Who can I contact for more information?
For investor inquiries, contact Justin Ng, and for media-related questions, Jenna Urban at Berry & Company Public Relations is the point of contact.
